Does Anavar cause hair loss? Oxandrolone — commonly known by the colloquial brand name Anavar — is a synthetic anabolic-androgenic steroid derived from dihydrotestosterone (DHT), and its androgenic activity means hair loss is a genuine concern for susceptible individuals. Although oxandrolone carries a relatively low androgenic rating compared with testosterone, it acts directly at the androgen receptor and can accelerate follicle miniaturisation in those with a genetic predisposition to androgenetic alopecia. This article explains the mechanism, who is most at risk, what the evidence shows, and what to do if you notice shedding.

How Anavar Affects Hair Follicles and Androgen Sensitivity

Oxandrolone is a DHT-derived compound that binds directly to scalp androgen receptors, potentially accelerating follicle miniaturisation and hair loss in genetically susceptible individuals, even at relatively low androgenic doses.

Not sure if this is normal? Chat with one of our pharmacists →

Oxandrolone — sold under the colloquial brand name Anavar — is a synthetic anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT). It is worth noting that 'Anavar' is not a currently licensed UK brand name; oxandrolone is not marketed in the UK, and products obtained outside a legitimate clinical setting may be counterfeit or of unknown quality.

Oxandrolone is a 17α-alkylated DHT derivative. Crucially, it acts directly at the androgen receptor and does not require conversion by 5-alpha reductase to exert its androgenic effects, nor is it aromatised to oestrogen. This pharmacological profile is directly relevant to hair loss.

Hair follicles on the scalp contain androgen receptors. In individuals who are genetically predisposed to androgenetic alopecia (commonly known as male- or female-pattern hair loss), DHT binds to these receptors and progressively miniaturises the follicle. Over time, this shortens the hair growth cycle and produces finer, shorter hairs until the follicle becomes dormant. Because oxandrolone is itself a DHT-derived compound that binds directly to androgen receptors, it can replicate this process and may accelerate hair follicle miniaturisation in susceptible individuals.

Oxandrolone has a relatively low androgenic rating compared with testosterone or more potent anabolic steroids. However, 'low' does not mean 'absent.' Even modest androgenic stimulation can be sufficient to trigger or worsen hair thinning in those who are genetically susceptible. Scalp sensitivity to androgens varies considerably between individuals, which is why some users report noticeable shedding whilst others experience little change in hair density. Mechanistic plausibility does not mean hair loss is inevitable — individual susceptibility is the key variable.

Who Is Most at Risk of Hair Loss When Taking Oxandrolone

Those with a family history of androgenetic alopecia, pre-existing thinning, higher doses, longer use, or concurrent androgens face the greatest risk; women are especially vulnerable to disproportionate hair and virilising effects.

Not everyone who uses oxandrolone will experience hair loss. Understanding individual risk factors is important for making an informed decision.

Androgenetic alopecia is a polygenic condition, meaning the genetic risk is inherited from both sides of the family — not predominantly the maternal line as is sometimes claimed. If close relatives on either side have experienced significant hair loss, your follicles may be more sensitive to androgenic compounds, including oxandrolone.

Key risk factors include:

• Family history of hair loss on either side of the family

• Pre-existing hair thinning or a receding hairline before starting the drug

• Higher doses of oxandrolone, as greater androgenic exposure increases risk (note: any non-medical use is unlicensed and carries additional safety risks)

• Longer duration of use, which prolongs androgenic exposure

• Concurrent use of other androgenic compounds, such as testosterone, which substantially increases the overall androgenic load

• Female sex, as women have lower baseline androgen levels, meaning even mild androgenic activity can produce disproportionate effects on scalp hair — and may also cause other virilising changes (see below)

Women using oxandrolone are at particular risk not only of diffuse hair thinning but also of other virilising adverse effects, including voice deepening, hirsutism, and clitoromegaly. Some of these changes may be irreversible even after stopping the drug. In the UK, oxandrolone is occasionally used under specialist supervision for specific clinical indications such as Turner syndrome (in paediatric and endocrine settings), recovery from severe burns, or HIV-associated wasting — not for osteoporosis, which is not a current UK indication. Younger men who have not yet shown signs of androgenetic alopecia may still carry the genetic predisposition and could find that oxandrolone accelerates the onset of hair loss.

Experiencing these side effects? Our pharmacists can help you navigate them →

What the Evidence Says About Oxandrolone and Androgenic Side Effects

Large-scale trial data are lacking, but androgenic alopecia is a recognised class-level adverse effect of anabolic steroids per BNF guidance, and the pharmacological mechanism supporting oxandrolone-related hair loss is well established.

The clinical evidence base specifically examining oxandrolone and scalp hair loss is limited. Most data on androgenic alopecia associated with anabolic steroids comes from case reports, observational studies, and extrapolation from broader research on DHT and androgenetic alopecia. There is no large-scale randomised controlled trial directly measuring hair loss as a primary outcome in oxandrolone users.

That said, androgenic alopecia is a recognised adverse effect of anabolic-androgenic steroids as a class. The British National Formulary (BNF) lists androgenic effects — including virilisation and changes to hair distribution — among the known risks of anabolic steroids as a drug class. Because oxandrolone is not currently marketed in the UK, there is no UK Summary of Product Characteristics (SmPC) for this specific product; adverse effect information should therefore be drawn from BNF class-level guidance and MHRA resources rather than a product-specific SmPC.

In clinical settings, oxandrolone has been used in populations such as those recovering from severe burns or with Turner syndrome. Studies in these groups have documented virilising adverse effects in women, including changes to scalp and body hair, reinforcing the biological plausibility of hair loss as a consequence of androgenic stimulation.

Whilst there is no definitive clinical trial confirming that oxandrolone causes hair loss at the same rate as more potent androgens, the pharmacological mechanism is well established and consistent with what the science would predict. Caution is therefore warranted, particularly in genetically susceptible individuals.

If you experience suspected adverse effects from oxandrolone or any other medicine or substance, you can report these to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. This applies even to unlicensed or illicitly obtained products.

Managing and Minimising Hair Loss During Oxandrolone Use

Stopping oxandrolone is the most effective strategy; topical minoxidil can support follicle function, while finasteride offers limited benefit because oxandrolone acts directly at the androgen receptor rather than via 5-alpha reductase.

For individuals using oxandrolone under medical supervision who are concerned about hair loss, several strategies may help reduce the impact. None can fully eliminate the risk in genetically predisposed individuals, and stopping oxandrolone is the most effective way to reduce ongoing androgenic stimulation. Hair loss that has occurred may be partially reversible after discontinuation, particularly if follicles have not yet become permanently dormant — early intervention offers the best chance of preserving hair density.

Pharmacological options used in the management of androgenetic alopecia include:

• Minoxidil (topical) — available over the counter in the UK, minoxidil prolongs the anagen (growth) phase of the hair cycle and can slow shedding. It does not block androgens but supports follicle function. It should not be used during pregnancy or breastfeeding, and an initial increase in shedding can occur when first starting treatment.

• Finasteride 1 mg — a 5-alpha reductase inhibitor licensed in the UK for male pattern hair loss only. It is contraindicated in women of childbearing potential and must not be used during pregnancy. Its utility against oxandrolone-related hair loss is limited in any case, because oxandrolone is itself a DHT derivative that acts directly at the androgen receptor and does not rely on 5-alpha reductase conversion. Finasteride may reduce endogenous DHT levels but will not counteract oxandrolone itself. Any use in women would be off-label and should only occur under specialist supervision.

• Ketoconazole shampoo — has mild anti-androgenic properties at the scalp level and is sometimes used as an adjunct, though evidence for its benefit in androgenetic alopecia is limited.

Practical measures include:

• Keeping doses as low as clinically appropriate and avoiding non-medical use

• Avoiding concurrent use of other androgenic compounds

• Monitoring hair density regularly and seeking medical advice early if shedding begins

Any use of oxandrolone outside a legitimate clinical prescription carries additional risks, including exposure to counterfeit or contaminated products.

When to Seek Medical Advice About Hair Loss

Consult your GP if hair loss is sudden, patchy, accompanied by systemic symptoms, or causing significant distress; referral to a consultant dermatologist is appropriate for scarring, atypical, or diagnostically uncertain cases.

Hair loss during or after anabolic steroid use should not be dismissed as a purely cosmetic concern. Significant or rapid hair shedding can indicate broader hormonal disruption, and appropriate medical assessment is important.

Contact your GP if:

• Hair loss is sudden, patchy, or accompanied by other symptoms such as fatigue, weight changes, or skin changes (which may suggest thyroid dysfunction or other endocrine conditions)

• You notice scalp pain, redness, scaling, pustules, or loss of eyebrows or eyelashes — these may indicate scarring alopecia, which requires prompt assessment

• Hair shedding is severe or causing significant psychological distress

• You are a woman experiencing hair thinning, as this warrants investigation to rule out other causes such as polycystic ovary syndrome (PCOS), iron deficiency, or thyroid disease

• You are using oxandrolone without a prescription and are experiencing adverse effects — your GP can provide non-judgemental support and referral

A GP may arrange blood tests including full blood count, ferritin, and thyroid function tests as clinically indicated. An androgen profile may be appropriate in women with features of hyperandrogenism or in individuals with suspected endocrine causes; routine sex hormone testing is not indicated for straightforward male androgenetic alopecia.

Referral to a consultant dermatologist with a specialist interest in hair disorders is appropriate for persistent, atypical, scarring, or diagnostically uncertain cases, or for severe female pattern hair loss. It is important to be aware that NHS funding for androgenetic alopecia treatments is limited; most management of straightforward pattern hair loss is self-funded, and NHS referral is typically reserved for atypical presentations, scarring alopecia, or significant diagnostic uncertainty. NICE CKS provides guidance on the assessment and management of female pattern hair loss and hair loss more broadly.

Psychological support should also be considered, as hair loss can have a significant impact on self-esteem and mental wellbeing.

UK Legal Status and Safer Alternatives

Oxandrolone is a Class C, Schedule 4 Part II controlled drug in the UK; possession for personal use is not a criminal offence, but supply and importation are, and it is not currently licensed for any UK indication.

In the United Kingdom, oxandrolone is a Class C controlled drug and is listed under Schedule 4 Part II of the Misuse of Drugs Regulations 2001. It is important to understand the legal position accurately:

• Possession for personal use of a Class C anabolic steroid is not a criminal offence under UK law

• Supply, production, and import/export (for example, ordering via post or courier from abroad) are criminal offences

• Oxandrolone is not currently marketed or licensed in the UK; any clinical use would require unlicensed specialist prescribing for a specific, justified indication

For further information on the legal status of anabolic steroids in the UK, refer to Home Office guidance.

Oxandrolone is not licensed for performance enhancement or bodybuilding purposes. Products obtained outside a legitimate clinical setting may be counterfeit, mislabelled, or contaminated.

For individuals seeking muscle-preserving or body composition benefits, evidence-based and legally available options include:

• Resistance training programmes tailored by a qualified strength and conditioning coach — the most effective and safest method of improving muscle mass and body composition

• Dietary protein optimisation and creatine monohydrate supplementation, which have robust evidence supporting their role in muscle development without androgenic risk

• Assessment for hypogonadism by a GP or endocrinologist, if there is a genuine clinical concern about testosterone deficiency — NICE CKS provides guidance on testosterone deficiency assessment and management

For those experiencing hair loss independently of steroid use, NICE CKS provides guidance on androgenetic alopecia, and topical minoxidil is a recognised first-line option. NHS services can provide assessment for atypical or complex cases.

If you are concerned about anabolic steroid use, the Talk to Frank service (talktofrank.com) and NHS drug services can provide confidential advice without judgement. The NHS website also provides information on the risks of anabolic steroid misuse. Speaking openly with your GP is always encouraged — making informed, medically guided decisions is the safest approach.

Frequently Asked Questions